Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

1.90USD
22 Nov 2017
Change (% chg)

$-0.02 (-1.04%)
Prev Close
$1.92
Open
$1.94
Day's High
$1.94
Day's Low
$1.89
Volume
812,956
Avg. Vol
1,031,823
52-wk High
$7.15
52-wk Low
$1.68

Chart for

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $468.65
Shares Outstanding(Mil.): 246.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017

* CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2A4qbNI) Further company coverage:

Nov 22 2017

BRIEF-Synergy Pharma announces pricing of offering of common stock and warrants

* Synergy Pharmaceuticals announces pricing of offering of common stock and warrants

Nov 13 2017

BRIEF-Synergy Pharma files for a potential mixed shelf offering ‍​

* Synergy Pharmaceuticals Inc files for a potential mixed shelf offering; size undisclosed - SEC filing ‍​ Source text: (http://bit.ly/2mihpZ2) Further company coverage:

Nov 13 2017

BRIEF-Synergy Pharmaceuticals posts Q3 loss per share $0.22

* Synergy Pharmaceuticals reports third quarter 2017 financial results and business update

Nov 09 2017

BRIEF-Synergy Pharmaceuticals secures $300 mln debt financing

* Synergy Pharmaceuticals secures $300 million debt financing

Sep 05 2017

BRIEF-Synergy Pharma Q2 sales $2.3 million

* Synergy Pharmaceuticals reports second quarter 2017 financial results and business update

Aug 09 2017

Earnings vs. Estimates